MXCT241220P7500
- 0.00
- 0.000.00%
MaxCyte Newsroom
This MaxCyte Insider Increased Their Holding In The Last Year
MaxCyte Celebrates 25 Years of Innovation Driving Cell Engineering-Based Therapeutics
BTIG Maintains MaxCyte(MXCT.US) With Buy Rating, Maintains Target Price $8
MaxCyte Weighs Delisting From AIM to Prioritize Nasdaq: Potential Benefits and Risks Ahead
Stifel Maintains MaxCyte(MXCT.US) With Buy Rating, Maintains Target Price $11
Craig-Hallum Maintains MaxCyte(MXCT.US) With Buy Rating, Announces Target Price $7
TD Cowen Maintains MaxCyte(MXCT.US) With Buy Rating
MaxCyte Inc (MXCT) Q3 2024 Earnings Call Highlights: Strong Core Revenue Growth Amidst Market ...
MaxCyte, Inc. (MXCT) Q3 2024 Earnings Call Transcript Summary
TD Cowen Initiates MaxCyte(MXCT.US) With Buy Rating
MaxCyte's Q3 Performance and Strategic Initiatives Signal Strong Growth Potential and Investment Opportunity
Express News | MaxCyte Inc: Expects to End 2024 With Approximately $185 Mln in Total Cash, Cash Equivalents and Investments
Express News | MaxCyte Expectes FY2024: Core Revenue Growth at Least 5% Vs. 2023; SPL Revenue ~$6M
MaxCyte GAAP EPS of -$0.11 Beats by $0.01, Revenue of $8.2M Beats by $0.84M
MaxCyte | 10-Q: Quarterly report
MaxCyte | 8-K: MaxCyte Reports Third Quarter 2024 Financial Results and Updates Full Year 2024 Guidance
Express News | MaxCyte Inc: Considering Costs and Benefits of Maintaining Dual Listings on Aim and Nasdaq
Express News | MaxCyte Inc: Evaluating and Executing on Opportunities to Reduce Its Cost Structure and Improve Operational Focus and Efficiency
Earnings Flash (MXCT) MAXCYTE Reports Q3 Revenue $8.2M
Express News | MaxCyte Reports Third Quarter 2024 Financial Results and Updates Full Year 2024 Guidance